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Abstract: Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive disease that 
occurs in individuals infected with the human T lymphotropic virus type 1 (HTLV-1). 
Patients with aggressive ATLL have a poor prognosis because the leukemic cells are 
resistant to conventional chemotherapy. We have investigated the therapeutic efficacy of a 
biphosphinic cyclopalladated complex {Pd2 [S(−)C
2
, N-dmpa]2 (-dppe)Cl2}, termed C7a, 
in a patient-derived xenograft model of ATLL, and investigated the mechanism of C7a 
action in HTLV-1-positive and negative transformed T cell lines in vitro. In vivo survival 
studies in immunocompromised mice inoculated with human RV-ATL cells and 
intraperitoneally treated with C7a led to significantly increased survival of the treated mice. 
We investigated the mechanism of C7a activity in vitro and found that it induced 
mitochondrial release of cytochrome c, caspase activation, nuclear condensation and DNA 
degradation. These results suggest that C7a triggers apoptotic cell death in both HTLV-1 
infected and uninfected human transformed T-cell lines. Significantly, C7a was not 
cytotoxic to peripheral blood mononuclear cells (PBMC) from healthy donors and  
HTLV-1-infected individuals. C7a inhibited more than 60% of the ex vivo spontaneous 
proliferation of PBMC from HTLV-1-infected individuals. These results support a 
potential therapeutic role for C7a in both ATLL and HTLV-1-negative T-cell lymphomas. 
Keywords: cyclopalladated compound; HTLV-1; ATLL; chemotherapy; xenograft model; 
apoptosis 
 
1. Introduction  
About 44,000 new cases of leukemia are expected in the United States in 2011. Nearly half of these 
will be acute leukemias, including adult T-cell leukemia/lymphoma (ATLL). ATLL is a highly 
aggressive disease characterized by the rapid and uncontrolled clonal proliferation of mature 
transformed CD25
+
CD4
+
 T-cells. Infection with human T lymphotropic virus type 1 (HTLV-1) is the 
major risk factor for the development of ATLL. Currently, approximately 15 million people in the 
world are infected with HTLV-1. Conventional chemotherapy or a combination of zidovudine (AZT) 
and interferon-alpha are the currently favored treatments for patients with ATLL, but are effective in 
only 50% of cases [1]. Additionally, the mean survival of patients in the acute phase of ATLL is 
approximately six months even with aggressive chemotherapy. Although targeting HTLV-1-infected 
cells for apoptosis is an attractive approach to treating ATLL, HTLV-1 infected cells are generally 
resistant to apoptosis induced by available drugs. Thus, it is important to develop new approaches to 
treat HTLV-1-infected patients diagnosed with ATLL and to specifically induce cell death in HTLV-1-
infected T-cells in vivo.  
Novel antitumor compounds that are cytotoxic to tumor cells in vitro must be tested in preclinical 
animal models to determine their availability and effectiveness in vivo. In the absence of a syngeneic 
murine model for ATLL, xenogeneic experimental models have been developed, using immunocompromised 
mice. Mice homozygous for the SCID mutation lack functional T and B lymphocytes, fail to generate 
humoral and cell-mediated immunity and have been widely used as hosts for both normal and 
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malignant human cells. Engraftment of SCID mice with patient-derived tumor cells provides an in vivo 
model in which to investigate the tumorigenic potential of HTLV-1-infected human lymphocytes and 
cell lines. Feuer and colleagues initially reported the development of lymphoma in C.B.-17 scid/scid 
mice inoculated with peripheral blood mononuclear cells (PBMC) from an ATLL patient [2,3]. This 
patient-derived ATLL line, termed RV-ATL, can be propagated and expanded in SCID mice and is a 
useful platform to test the efficacy of novel therapeutic treatments on ATLL. Further refinement of the 
SCID mouse model by removing the interleukin (IL)-2 receptor generated NOD.Cg-Prkdc
scid
 
Il2rg
tm1Wjl
/SzJ (NSG) mice. NSG mice lack functional NK cells and are deficient in cytokine signaling, 
which supports better engraftment of human hematopoietic stem cells and PBMCs [4,5]. These mice 
also support the propagation and expansion of RV-ATL-cells.  
Recently, several palladium (Pd) complexes have been evaluated as antitumor agents [6,7], but only 
a few of them have been tested in preclinical animal models. Cyclization of Pd complexes by 
cyclometallation reactions not only increased the stability but also produced less toxic complexes, 
making them promising antitumor compounds [8]. A group of biphosphinic cyclopalladated 
compounds, obtained from the cyclometallation agents, N,N-dimethyl-1-phenethyl-amine (dmpa), 
phenyl-2-pyridinyl-acetylene or 1-phenyl-3-N,N-dimethylamine-propyne and containing the biphosphinic 
ligand 1, ethanebis(diphenyl-phosphine) (dppe), were synthesized and tested in vitro and in vivo in a 
syngeneic murine melanoma B16F10-Nex2 model. One complex, [Pd(C2,N-(S(-) dmpa)(dppe)].Cl, 
named C7a, was cytotoxic to murine B16F10 melanoma cells in vitro at concentrations lower than  
1.25 M, and was the most active in vivo, delaying subcutaneous tumor growth and increasing animal 
survival [9]. More recently, we demonstrated that C7a reduced the number of pulmonary nodules in 
the murine metastatic melanoma model, and interacted with mitochondrial membrane thiol-groups to 
induce the intrinsic apoptotic death pathway in murine and cisplatin-resistant human tumor cells [10]. 
Hebeler-Barbosa et al. demonstrated the additive anti-melanoma protective effect of C7a in a gene 
therapy protocol with plasmids encoding IL-12 and an Fc-chimera of the soluble -chain of IL-13 
receptor. The combined therapy significantly reduced the subcutaneous tumor evolution with 30% 
tumor-free mice [11].  
The present study investigates the effect of C7a in an ATLL mouse model and the mechanism of 
cell death induced by C7a in HTLV-1-infected and uninfected T cell leukemia lines. We show that 
treatment with C7a significantly increased the survival of RV-ATL engrafted mice and that C7a 
induced caspase-mediated apoptosis of human transformed T-cell lines and HTLV-1 infected T cells. 
These results support a potential therapeutic role for C7a in both ATLL and HTLV-1-negative  
T-cell lymphomas. 
2. Results 
2.1. C7a Is Cytotoxic to Human Leukemia T Cell Lines 
Because HTLV-1 infected transformed T cells are difficult to control with available 
chemotherapeutic strategies, we evaluated the cytotoxic effect of C7a on HTLV infected cell lines  
in vitro. C7a was cytotoxic to all cell lines in a dose-dependent manner (Figure 1A) suggesting that 
established human T cell lines are susceptible to C7a whether or not they are infected with HTLV-1. 
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Although C7a did not kill 100% of any of the cell lines analyzed, even at the highest concentration 
tested, 7.5 M C7a reduced the viability of most cell lines by 90% after 48 h. Uninfected CEM T cells 
were most resistant to C7a cytotoxicity, with 40% of the cells remaining viable at 60 M C7a. 
Importantly, C7a had minimal cytotoxic effect on the viability of HTLV-1 infected or uninfected 
primary human PBMC, with >80% of the cells remaining viable even at 60 M C7a (Figure 1A).  
In a similar dose-dependent cytotoxicity study to examine the cytotoxicity of C7a, 40 M C7a  
reduced the viability of RV-ATL cells, a patient-derived HTLV-1-infected ATLL cell line, by 90% 
after 48 h (Figure 1B).  
Figure 1. Cyclopalladated C7a is cytotoxic to human leukemia cell lines, but has little effect 
on human T lymphotropic virus type 1 (HTLV-1)-infected or uninfected peripheral blood 
mononuclear cells (PBMC). (A) 5 × 10
5
 PBMC (previously stimulated with PHA and IL-2) 
from three donors (HTLV-1 uninfected), 10
5
 cells from human T cell leukemia lines, and 
10
5
 PBMC from four different HTLV-1-infected individuals were seeded in 96-well plates 
in triplicate. Cells were incubated with concentrations of C7a as indicated for 48 h, and 
cytotoxicity was determined by Trypan blue exclusion in an automated cell counter. The 
bars represent the means and SD of three different experiments; (B) RV-ATL cells were 
expanded in a SCID mouse for three weeks. Freshly harvested cells were seeded at 10
5
 cells 
per well in a 24-well plate. The cells were incubated with concentrations of C7a as indicated 
for 48 h. Uninfected human Jurkat T cells were used as a control and incubated in the same 
conditions. Cytotoxicity was determined by Trypan blue exclusion and manual counting. A 
representative experiment is shown. The experiment was repeated twice, using two 
independent frozen tissue culture stocks of RV-ATL cells and without refreshing the media 
or drug, with comparable results. In (A) and (B), the viability of treated cells was expressed 
as percent of control untreated cells.  
 
2.2. C7a Is Effective in a Preclinical Model of ATLL 
Since C7a could kill RV-ATL cells in vitro, we next evaluated the effect of C7a on the development 
of leukemia in vivo using a xenogeneic murine model [2,3]. RV-ATL cells (10
7
), previously expanded 
in vivo in NOD.Cg-Prkdc
scid
 Il2rg
tm1Wjl
/SzJ (NSG) mice, were intraperitoneally inoculated on day 0 in 
23-week old NSG mice. The engraftment of mice with RV-ATL cells was monitored by peritoneal 
lavage at days 14, 28 and 42. Collected cells were analyzed by flow cytometry for previously 
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determined phenotypic markers and were huCD45
+
, huCD4
+
, huCD8
-
 and huCD25
low
 (data not 
shown). All mice were successfully engrafted. 
NSG mice engrafted with RV-ATL cells were divided into four groups (five mice per group). Each 
group of mice was inoculated with the same dose of C7a diluted in 100 L of PBS, regardless of body 
weight, and drug concentration per gram of mouse body weight was not statistically different based on 
weekly weight measurements (data not shown). All mice were monitored daily for clinical assessment 
and survival. Animals in group 1, which did not receive any C7a, had an average survival of 24 days 
post-inoculation (Figure 2), and none of the mice survived beyond day 27 (blue line). Animals in 
group 2, which received 20 M C7a every other day beginning on day 4 through day 40, survived 
significantly longer than animals in group 1 (p value = 0.049), with all animals surviving to day 34 and 
two animals still alive at termination of the study (red line). Animals in group 3 did not receive C7a 
until day 22, which allowed tumor expansion prior to treatment. These animals then received 80 M 
C7a every other day from day 22 through day 40 (green line). Animals in group 3 survived longer than 
animals in group 1 that did not receive any C7a. Although three animals did not survive past day 31, 
the remaining two animals in group 3 were still alive at termination of the study suggesting that a 
higher dose of C7a late in tumor development can protect a significant fraction of animals.  
Figure 2. C7a significantly increases the survival of RV-ATL tumor bearing mice. Adult 
female NSG mice were intraperitoneally (IP) injected with 10
7
 fresh, in vivo expanded  
RV-ATL cells on Day 0. Mice were treated with either C7a (20 μM diluted in PBS) (red 
line and purple line) or PBS alone (blue line and green line) by IP injection every other day 
starting on Day 4. Starting on day 22, half the mice from each group were treated with  
80 μM C7a (green line and purple line). N = 5 per group for four treatment groups. All 
mice were treated by IP injections through day 40, and survival was monitored daily.  
p values (Kaplan Meier test) are shown for each group, compared to no treatment group. 
 
 
Animals in group 4 received 20 M C7a every other day from day 4 to day 20, and 80 M C7a 
every other day from day 22 to day 40 (purple line). These animals showed the best survival, with four 
of the five animals in this group still alive at termination of the study. Pairwise comparison of the 
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treatment groups showed that the survival of animals in group 4 was significantly better than those in 
group 1 (p value = 0.018). In all groups, animal deaths were attributed to tumor burden. Clinical signs 
prior to death included distended abdomen due to tumor growth, weight loss, dragging of hind limbs 
(necropsy showed tumor pressing on thigh muscles and/or spinal cord). There was no evidence of 
clinical signs that were not tumor related.  
2.3. C7a Induces the Intrinsic Apoptotic Pathway in Human T Cell Leukemia Lines 
Treatment of HL-60 cells, which were effectively killed by 7.5 M C7a (Figure 1), with 2 M C7a 
for 7 h resulted in profound morphologic alterations observed by transmission electron microscopy. 
Treated cells showed chromatin margination, and an increase in enlarged vacuoles and electron-dense 
material in the cytoplasm (Figure 3A). Externalization of phosphatidylserine (PS), which is normally 
restricted to the inner leaflet of the plasma membrane, is a hallmark of mammalian apoptosis. Cell 
lines were treated with C7a for 3 h, and PS exposure was analyzed by double staining the cells with  
7-amino-actinomycin (7-ADD), a vital dye, and PE-annexin V, a Ca
2+
 dependent phospholipid-binding 
protein that has a high affinity for PS (Figure 3B). A dose-dependent decrease in the number of live 
cells (PE-annexin negative and 7-ADD negative) and an increase in the number of cells in late 
apoptosis (PE-annexin positive and 7-ADD positive) were observed in MT-2, C81, and Jurkat cell 
lines treated with C7a for 3 h (Figure 3B). The morphological changes, and the PS exposure observed 
in C7a-treated T cell leukemia lines suggested that this cyclopalladated complex can induce apoptosis 
in these cells, as observed previously for murine melanoma cells. 
To determine the effect of C7a on mitochondria of intact HTLV-1-infected T cell leukemia lines, 
MT-2 cells were incubated in vitro with 5 M C7a for 3 h. In untreated cells, cytochrome c colocalized 
with the mitochondrial marker (top row, see white arrow) (Figure 4A). In contrast, in cells treated with 
C7a, cytochrome c was predominately localized in the cytoplasm and did not colocalize with the 
mitochondrial marker (bottom rows). These results suggest that C7a can induce mitochondrial 
permeabilization and release of mitochondrial contents. 
C7a-induced apoptosis was associated with caspase activation in MT-2 cells, as the caspase-3 
precursor was cleaved into the 17 and 19 kDa death-associated fragments (Figure 4B). C7a similarly 
induced activation of caspase 3 in HL-60 cells as well as activated caspases -8 and -9 (data not shown). 
Although DTT showed a partial toxicity to MT-2 cells, C7a -mediated cytotoxicity was abolished by 
DTT treatment in both cell lines (Figure 4C), suggesting that this cyclopalladated complex can induce 
thiol-cross-linking of mitochondrial membrane proteins resulting in mitochondrial permeabilization in 
leukemia cells, as previously described in murine melanoma cells treated with the R(+) enantiomer of 
C7a [12]. 
To investigate whether the lysosomal pathway plays a role in apoptotic cell death induced in 
leukemia cells by C7a, the cytotoxic effect of C7a was evaluated in MT-2 and HL-60 cells after 
preincubating with a cathepsin B inhibitor (CA-074). The cytotoxic effect of C7a was not influenced 
by the inhibitor, indicating that the lysosomal pathway is not involved in C7a-mediated apoptosis of 
malignant T cells (data not shown).  
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Figure 3. C7a induces morphological and phenotypic alterations compatible with apoptosis 
in human leukemia cell lines. (A) Transmission electron microscopy. (1) HL-60 cells 
cultivated in complete RPMI medium for 6 h; (2 and 3) HL-60 cells cultivated in presence 
of 2 M C7a for 7 h. Black arrows: nuclear condensation; White arrows: vacuoles. This 
assay was repeated twice, and representative images are shown; (B) Membrane 
phosphatidylserine expression. HTLV-1 infected MT-2 and C81, and uninfected Jurkat cell 
lines (1 × 10
6
) were incubated in the presence of C7a at the indicated concentrations for 3 h 
at 37 °C. After staining with PE-Annexin V and 7-AAD, cells were analyzed by flow 
cytometry, as described in Material and Methods. A representative of two independent 
experiments is shown. 
 
 
Nuclear effects of C7a were evaluated in human leukemia T cell lines. Nuclear condensation was 
observed in HL-60 cells treated with 5 M C7a for 6 h (Figure 5A, panel 2) and chromosomal 
fragmentation was observed after 24 h (Figure 5A, panel 4), while few cells showed such patterns in 
control untreated cells (Figure 5A, panels 1 and 3). After treatment with 5 M C7a for 18 h, HL-60 
cells showed DNA internucleosomal fragmentation (Figure 5B, lane 3). Upon propidium iodide 
staining, fluorescence intensity in FACS-analyzed cells varies linearly with DNA content, ranging 
from 2 n (G0-G1 phases) to 4 n (G2 phase) with an intermediate plateau that corresponds to S phase. 
The sub-G1 peak in DNA histograms corresponds to the apoptotic population. Exposure of HTLV-1 
infected C81 cells to 1.25 M C7a for 48 h induced an 8-fold increase in the sub-G1 peak (Figure 5C, 
bottom panel), again demonstrating that C7a induces apoptosis in these cells. Taken together, these 
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results show that C7a induces the intrinsic apoptotic pathway in human leukemic T cell lines, with no 
participation of the lysosomal pathway. 
Figure 4. Mitochondria are involved in C7a induced cell death. (A) Cytochrome c release. 
HTLV-1 infected MT-2 cells were incubated without (0 M) or with 5 μM C7a for 3 h. 
The cells were fixed and incubated with anti-cytochrome c antibody (green). Mitochondria 
were detected by MitoTracker staining (red), and nuclei were visualized with DAPI (blue). 
Magnification (×40). Inserts: Single cell indicated by the arrow, magnification (×60). Rare 
cells treated with C7a that show colocalization of cytochrome c and mitochondria likely 
reflect the short 3 h exposure to C7a. The assay was repeated twice, and representative 
images are shown; (B) Caspase Activation. Cell lysates from MT-2 cells before treatment 
(Control), after treatment with 5 M C7a for 3 h, or after exposure to 50 J of UV light 
(UV), as a positive control, were analyzed by Western blotting for cleaved caspase-3 and 
GAPDH as a loading control. This assay was repeated twice, and representative images are 
shown; (C) DTT inhibits C7a effect on leukemic human T cells. MT-2 (HTLV-1 infected) 
and uninfected HL-60 cells (10
5
) were pre-incubated or not with 1 mM of DTT for 1 h. 
C7a was added to the culture (15 M to MT-2, 2 M to HL-60 cells) and incubated for 6 h. 
Viable cells were counted in presence of Trypan Blue in a hemocytometer. The bars 
represent the means and SD of three different experiments.  
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Figure 5. C7a induces nuclear alterations characteristic of apoptosis. (A) Nuclear 
condensation. Uninfected HL-60 cells were untreated (1) or treated with 5 μM C7a (2) for 
6 h. Alternatively, HL-60 cells were untreated (3) or treated with 2.5 μM C7a (4) for 24 h. 
After incubation with C7a, cell nuclei were stained with Hoechst 33342. Inserts: Single cell 
indicated by the arrow, ×25 magnification. The assay was repeated three times, and 
representative images are shown; (B) DNA fragmentation. HL-60 cells (3 × 10
6
) were 
treated (lane 3) with 5 μM of C7a or not (lane 2) for 18 h. Lane 1: MW standard. The assay 
was repeated three times, and a representative gel is shown; (C) Cell cycle analysis.  
HTLV-1 infected C81 cells were cultured with 1.25 M C7a (bottom panel) or not (top 
panel) for 48 h. Cells were stained with propidium iodide (50 g/mL) and cell cycle analysis 
was performed by flow cytometry. Percentage of cells in each phase of the cycle is shown. 
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2.4. C7a Treatment Reduces Spontaneous Proliferation of PBMC from HTLV-1-Infected Patients  
C7a does not have a cytotoxic effect on PBMC from healthy HTLV-1-infected individuals  
(Figure 1A). However, C7a was able to reduce the spontaneous in vitro proliferation of PBMC from 
HTLV-1-infected individuals (Figure 6). Spontaneous proliferation of HTLV-1-infected PBMCs was 
reduced to 60% after 24 h incubation with the lowest C7a concentration evaluated (0.9 M) and 
reached 90% with 30 and 60 M concentrations of C7a.  
Figure 6. In vitro inhibition of spontaneous proliferation of PBMC from HTLV-1-infected 
patients by C7a. Isolated PBMC from HTLV-1-infected individuals were cultured in the 
presence or absence of C7a compound for 24 h. Bars represent average inhibition and 
standard deviation from four patients, compared to cells from the same patient cultivated in 
the absence of C7a. 
 
3. Discussion 
Recently, a number of new compounds and therapies have been shown to specifically induce 
apoptosis in HTLV-1 infected cells and in ATLL leukemic cells [13]. Here we have demonstrated that 
RV-ATL engrafted mice treated with C7a, a biphosphinic cyclopalladated compound, demonstrated up 
to 80% survival over the course of the study, with significantly greater protection against  
tumor-mediated death than untreated mice. In addition, we demonstrated that C7a effectively induced 
mitochondria-dependent apoptosis in human HTLV-1-infected T cells. Interestingly, C7a also induced 
the same effects in human transformed cell lines that are not HTLV-1-infected, such as acute  
T-lymphoblastic leukemia HL-60, CEM and Jurkat.  
Although important progress has been made in the treatment of ATLL such as combination therapy 
with AZT and IFN-α [14], immunotherapy with anti-IL-2 receptor or anti-CC chemokine receptor 4 
monoclonal antibodies [15], allogeneic bone marrow or stem cell transplantation [16] and apoptosis 
induction [17–21], ATLL remains highly intractable to conventional therapeutics. Testing of novel 
compounds against cancer in vivo requires the use of preclinical animal models. Establishment of 
newer strains of immunocompromised mice capable of supporting efficient levels of engraftment of 
ATLL cells from patients has accelerated the testing of drugs and targeted therapy against ATLL [22]. 
To test the antitumor effects of C7a in an in vivo model of ATLL, we used an established ATLL 
patient-derived xenograft model in immunocompromised (NSG) mice [2,3]. NSG mice injected 
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intraperitoneally with RV-ATL cells develop lymphoma associated with the mesenteric and pancreatic 
lymph nodes, liver and spleen. Significantly, mice treated with low dose C7a (20 μM) for the duration 
of the study had a 35% greater survival than untreated mice. Interestingly, mice that were untreated for 
the first half of the study and started on high dose (80 μM) C7a at day 22 (only two days prior to the 
average death of untreated mice) survived longer than untreated mice. Forty percent of these mice 
survived for the duration of the study suggesting that C7a is also effective against established tumors. 
Over the last 15 years studies showed that arsenic trioxide (As2O3), alone or in combination with 
other pro-apoptotic stimuli, induces apoptosis in HTLV-1-infected cells lines [23,24] and have been 
examined as possible treatments for ATLL. As2O3 induces apoptosis leading to cytochrome c release 
and caspase activation [25]. Previous studies demonstrated that a combination of As2O3 and IFN-, 
known to trigger Tax proteolysis, cures Tax-driven ATLL in mice [26]. However clinical use of 
arsenic is problematic as there are differences in sensitivity to As2O3, and arsenic itself is toxic at high 
doses [13]. C7a and the R(+) enantiomer complex have been described as potent inducers of apoptosis 
through targeting of the mitochondria by interacting with thiol-groups in the mitochondrial membrane 
of murine melanoma cells [10], and in rat isolated mitochondria [12], respectively. Treatment of 
isolated rat liver mitochondria with the R(+) enantiomer of C7a, {Pd2 [R(+)C
2
, N-dmpa]2 (-dppe)Cl2} 
results in mitochondrial permeabilization as indicated by Ca
+2
- and ROS-independent mitochondrial 
swelling, release of cytochrome c, dissipation of the mitochondrial transmembrane potential, 
uncoupling of oxidative phosphorylation, and mitochondrial calcium release [12]. Additionally, an 
ionic cyclopalladated compound with a ferrocene ligand {[Pd(C2,N-(S(-) dmpa)(dppf)] Cl}] (termed 
BPC) induces apoptosis in acute leukemia cells through a novel lysosomal pathway with cathepsin B 
acting as the death mediator [27]. The C7a complex used in this study induces mitochondrial-
dependent, lysosomal-independent, apoptosis in HTLV-1-infected and uninfected transformed cell 
lines as characterized by the cleavage of caspase 3 and release of cytochrome c. Thus, while 
cyclopalladated compounds have been clearly demonstrated to induce apoptosis by activating a variety 
of cellular pathways, C7a is the only compound that has demonstrated antitumor effects in vivo [9].  
A hallmark of HTLV-1-infection is the spontaneous proliferation of peripheral blood mononuclear 
cells (PBMC) that is observed in approximately 50% of HTLV-1-infected individuals [28]. We  
found that C7a could inhibit more than 80% of the spontaneous proliferation of PBMC from  
HTLV-1-infected individuals, the majority diagnosed with HAM/TSP disease. The mechanisms 
involved in the inhibition of spontaneous proliferation by C7a remains unclear and further studies are 
necessary to elucidate the mechanisms of action of this drug on cell proliferation.  
Since C7a is capable of inducing mitochondrial-dependent apoptosis in acute leukemia cells  
(HL-60), and peripheral T-cell lymphomas have a low response rate to anthracyclin-based combination 
chemotherapy and high relapse rate [29], C7a offers an exciting alternative for treating other peripheral 
lymphomas. Further studies to test the efficacy of C7a in in vivo leukemia models are required.  
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4. Experimental Section 
4.1. Culture Conditions for Human Leukemia Cell Lineages and PBMC Isolation 
Peripheral blood mononuclear cells (PBMC) from heparinized venous blood of three healthy 
controls were isolated by Ficoll-Hypaque density gradient centrifugation (Pharmacia Biotech, Uppsala, 
Sweden). PBMC were in vitro stimulated for 3 days with 2 μg/mL phytohaemagglutinin (PHA) and 
subsequently cultured with 10 U/mL human recombinant IL-2 (both from Sigma-Aldrich, St. Louis, 
MO, USA) for 2 more days. PBMC from one asymptomatic HTLV-infected individual and seven 
patients diagnosed with HAM/TSP were obtained from heparinized venous blood samples by SepCell 
density gradient centrifugation (LGCBiotechnology, São Paulo, Brazil). Samples were screened for 
HTLV-1/2 antibodies by an enzyme-linked immunosorbent assay (ELISA) (Ab-Capture ELISA test 
system; Ortho-Clinical Diagnostics, Inc., Raritan, New Jersey, USA), and results were confirmed by 
Western blotting assay (HTLV Blot 2.4; Genelabs Technologies, Singapore). All patients presented 
high proviral load (>5000 copies/10
6
 PBMCs). The Ethical Board of Oswaldo Cruz Foundation 
(FIOCRUZ) approved this study, and informed consent was obtained from all enrolled patients. 
Immortalized human cell lines used in this study were HTLV-infected T cell lines (C81, HUT 102 and 
MT-2) and non-infected T cell leukemia lineages (CEM, HL-60 and Jurkat). Cell lines as well as 
PBMC were cultured in vitro in complete RPMI medium (RPMI 1640 medium supplemented with  
2 mM L-glutamine, 1% non-essential amino acids, 1mM sodium pyruvate, 100U/ml penicillin,  
100 μg/mL streptomycin and 10% fetal bovine serum, all provided by Sigma-Aldrich). PBMC from 
HTLV-infected patients were cultured in vitro in RPMI 1640 medium supplemented with 5% human 
group AB serum.  
RV-ATL cells were isolated from an ATL patient and expanded in SCID mice as previously 
described [2,3]. The RV-ATL cell line was further modified by the addition of a luciferase cassette 
[30]. The full phenotype of the RV-ATL cell line is human CD45
+
, CD4
+
, CD8
low
, CD25
low
 [2]. This 
tumor line was originally derived from PBL from a patient with acute leukemia. The phenotype of the 
RV-ATL cell line used in this study is human CD45
+
, CD4
+
, CD25
low
, which is comparable to both the 
primary derived RV-ATL cell line and to the malignant lymphocytes from the original patient. 
CD25
low
 expression is a reflection of the specific patient from which these cells were derived. This 
RV-ATL cell line is the same malignant clone derived from the original patient sample as molecularly 
determined by Southern blot analysis of HTLV integration. RV-ATL cells were cultivated for short 
term in vitro experiments in IMDM medium supplemented with 10% fetal bovine serum and  
100 U/mL penicillin/streptomycin/glutamine.  
Cyclopalladated compound. The cyclopalladated complex C7a was synthesized from N,N-dimethyl-1-
phenethylamide (dmpa), complexed to 1,2 ethanebis (diphenylphosphine, dppe) ligand, as previously 
described in [9]. The compound was diluted to a final concentration of 10 mM in DMSO (cell culture 
tested, Sigma Aldrich), and for in vivo and in vitro assays diluted to the final concentration in media  
or PBS. 
In vitro cellular toxicity assay. To evaluate the cytotoxic effects of C7a on PBMC (HTLV-1 positive 
and HTLV-1 negative individuals) and in malignant human T cell lineages, 1 or 5 × 10
5
 cells were 
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seeded in 96-well plates in triplicate, serial dilutions of C7a (ranging from 0.9 to 60 M) were added 
and plates were incubated for 48 h. Cellular viability was measured by Trypan Blue exclusion dye 
using the automated cell counter Vi-Cell XR Viability Analyzer (Beckman Coulter
®
). Control cells 
were incubated in the absence of C7a, and considered to be 100% viable. RV-ATL cells were 
expanded by intraperitoneal inoculation of SCID mice for 3 weeks and freshly harvested cells were 
plated at 10
5
 cells per well in a 24-well plate. For additional studies, RV-ATL cells were thawed from 
frozen stocks, plated in IMDM with 10% FBS and 1% P/S/G for 6 h at 37 °C prior to treatment with 
C7a. All RV-ATL cells were incubated in the presence of C7a at concentrations between 0 and 80 M, 
diluted in complete culture IMDM media at 37 °C for 48 h. Cytotoxicity was determined by Trypan 
blue method in a hemocytometer. C7a compound was diluted in complete culture media, and plates 
were incubated at 37 °C in a 5% CO2 humidified atmosphere. To verify the inhibitory effect of 
dithiothreitol (DTT) or a lysosomal cathepsin B inhibitor (CA-074) on C7a cytotoxicity in vitro, 10
5
 
MT-2 or HL-60 cells were pre-incubated with 1 mM DTT for 1 hour or with 10 mM CA-074  
[N-(L-3-trans-propylcarbamoyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline] for 2 h (both from Sigma 
Aldrich). C7a was added to MT-2 (15 M) and HL-60 cells (2 M) and incubated for 6 (DTT) or 18 h 
(CA-074). Viable cells were counted by Trypan Blue exclusion in a hemocytometer. Assays were done 
in triplicate, and repeated three times.  
RV-ATL SCID Mouse Studies. The animal research described in this manuscript was performed 
according to the guidelines for the Committee for Humane Use of Animals at SUNY Upstate Medical 
University in accordance with all federal, state and local guidelines. NOD.Cg-Prkdc
scid
 Il2rg
tm1Wjl
/SzJ 
(NSG) mice were obtained from our own breeding colony (breeder mice originally from Jackson 
Laboratories). All mice were housed under specific pathogen-free conditions. Prior to all 
manipulations, mice were anesthetized with isofluorane. RV-ATL cells from frozen stocks were 
expanded intraperitoneally in NSG mice prior to injection of study mice. Age-matched (22.5 to  
23 week old) female NSG mice were intraperitoneally (IP) injected with 10
7
 RV-ATL cells on day 0. 
Mice were treated with 100 L of PBS (with or without C7a) by IP injection every other day from day 
4 through 42. Drug concentration per gram of mouse body weight was not statistically different based 
on weekly weight measurements (data not shown). Tumor cells were removed by peritoneal lavage 
using PBS at two-week intervals (study days 14, 28 and 42). Mice were euthanized by carbon dioxide 
exposure as necessary due to tumor burden or severe clinical symptoms (usually dehydration). 
Remaining mice were euthanized on day 42 upon termination of the experiment.  
Transmission Electron Microscopy analysis. For transmission electron microscopy (TEM) analysis, 
HL-60 cells (5 × 10
6
) were cultured in presence or absence of 2 µM C7a for 6 h in complete RPMI 
medium. Cells were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, and 
post-fixation was performed using 1% osmium tetroxide, 0.08% potassium ferricyanide, 5 mM 
calcium chloride in the same buffer for 60 min in the dark (all reagents from Sigma-Aldrich). Cells 
were dehydrated using an acetone series and infiltrated in polybed epoxy resin (Polysciences, PA, 
USA). Ultrathin sections obtained by ultramicrotomy were collected on 300 mesh grids and stained 
with uranyl acetate and lead citrate for contrast. The ultrastructure analysis was done in a transmission 
electron microscope (Zeiss EM-900).  
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Cytochrome c release assay. MT-2 cells, cultured in round coverslips (24 mm), were preincubated for 
30 min with 62.5 nM MitoTracker (Molecular Probes, Eugene, OR) and then treated with 5 M of C7a 
for 3 h. The cells were washed once with PEM buffer [80 mM piperazine-N,N′-bis(2-ethanesulfonic) 
acid pH 6.8, 5 mM EGTA pH 7.0, 2 mM MgCl2], and fixed for 30 min at 4 °C with 5% formaldehyde 
diluted in PEM buffer. Cells were washed three times in PEM buffer, and permeabilized for 30 min at 
room temperature in PEM buffer containing 0.5% Triton X-100. Anti-cytochrome c antibody (1:800, 
Cell Signaling, MA, USA) diluted in 5% BSA and 0.1% Tween 20-containing TBS (TBS-T) was 
incubated overnight at 4 °C. After washing three times in TBS-T, cells were incubated for 2 h at room 
temperature in the dark with a fluorescein isothiocyanate-conjugated anti-rabbit IgG Alexa 488 (1:400, 
Sigma-Aldrich, MO USA) diluted in 5% BSA-containing TBS-T. Coverslips were washed three times 
with TBS-T, cells were counter-stained with DAPI (Sigma-Aldrich) and mounted on slides using 
Slow-Fade Anti-fade Mounting Media (Molecular Probes). Deconvolution images were taken using 
Olympus IX71 with 60X oil objective (NA = 1.42). All images were deconvolved using Delta Vision 
software (Applied Precision) using Ratio (conservative) method, with medium noise filtering for 6 
cycles and correction applied. Single staining images were processed by the ACDsee software (ACD 
Systems, Canada).  
Detection of caspase-3 activation. MT-2 cells were treated or not with 5 M of C7a for 1, 2 or 3 h. 
Alternatively, cells were exposed to 50J of UV light for 5 seconds as a positive control. Cell extracts 
were prepared as described in [31] and separated by electrophoresis in 0.1% SDS, 12% polyacrylamide 
gels. Proteins were blotted onto nitrocellulose membranes, and subsequently blocked for 1h at room 
temperature with 5% BSA in TBS-T. Membranes were incubated with an antibody against cleaved 
caspase-3 (CellSignaling, MA, USA), and GAPDH as a load control (Sigma-Aldrich MO, USA), 
diluted 1:1000 in TBS-T, 5% skim milk), overnight at 4 °C. After washing with TBS-T, the membranes 
were incubated with anti-rabbit Ig conjugated to horseradish peroxidase (Sigma Aldrich, diluted 1: 
40000 in TBS-T, 5% skim milk). After 1 h incubation at room temperature, the membranes were 
washed extensively with TBS-T, and developed with ECL (GE Healthcare) according to the 
manufacturer’s instructions.  
4.2. Analysis of Nuclear Alterations  
Hoescht 33342 staining: HL-60 cells (1 × 10
6
) were plated in 12 wells plate and treated or not 
(control) with 2.5 M C7a for 6 h or 5 µM for 24 h. Cells were then collected, washed 3 times in PBS 
and collected on round coverslips by centrifugation at 3000 rpm for 10 min. Cells were fixed for  
15 min in 2% formaldehyde and 30 min in absolute methanol, washed and stained with Hoescht 33342 
(Sigma-Aldrich MO, USA) for 15 min. Coverslips were mounted on glass slides with Vectashield  
(4 µL), sealed with nail polish and immediately analyzed in a fluorescent Olympus BX61 microscope 
(magnification 400X) at 360 nm. The images were acquired using Cell^M Software. 
DNA degradation assay: HL-60 cells (3 × 10
6
) were incubated with 5 µM C7a at 37 °C for 18 h in  
6 well-plates. Cells were recovered from the culture supernatant by centrifugation, lysed in TELT 
buffer (50 mM Tris-HCl pH 8.0, Triton X-100 0.4%, 2.5 mM EDTA pH 9.0 and 2.5M LiCl), and 
centrifuged for 15 min at 12000 g/4 °C. DNA was extracted by phenol-chloroform and precipitated 
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with 0.1 volume of 3 M sodium acetate, pH 7.0, and 2.5 volumes of absolute ethanol, following 
incubation at −80 °C for 20 min. All reagents were obtained from Sigma-Aldrich. Precipitated DNA 
was centrifuged, diluted in RNase-free water (25 μg/mL), separated by electrophoresis on a 1% 
agarose gel (100V) and photographed with a digital camera (Kodak, EDAS DC290).  
4.3. Flow Cytometry Analysis 
Cell-cycle analysis. C81, Jurkat, HL-60 and MT-2 cells (1 × 10
6
)
 
were cultured in the absence or 
presence of 2.5 M C7a for 48 h in 24 well-plates at 37 °C in a 5% CO2 humidified atmosphere. Cells 
were then collected, fixed in chilled methanol, and suspended in solution containing RNase A  
(100 U/mL; Sigma Aldrich) before staining with 50 g/mL of propidium iodide. A minimum of  
1 × 10
5
 cells were acquired by flow cytometry in a FACSCanto and data was analyzed using the 
FACSDiva software (Becton Dickinson, Mountain View, CA). 
Assessment of tumor burden in RV-ATL engrafted mice. Tumor burden in RV-ATL engrafted mice was 
assessed by flow cytometric analysis of peritoneal lavage cells. Engrafted cells were harvested by 
peritoneal lavage, washed with PBS and blocked in PBS containing 5% each human and murine serum 
for at least 20 min at 4 °C. RV-ATL cells were identified by staining with antibodies for human CD45, 
human CD4 and human CD25 compared with murine CD45 (all antibodies from Biolegend) for at 
least 30 min at 4 °C. Cells were washed twice with PBS and fixed for 15 min at 4 °C in 2% formalin in 
water then acquired on an LSRII flow cytometer (Becton Dickinson) and analyzed by FlowJo software 
(TreeStar, Ashland, CA). 
Detection of phosphatidylserine translocation by PE-Annexin V/7-AAD. C81, Jurkat and MT-2 cells 
were incubated in the presence of C7a at concentrations ranging from 0 to 15 M at 37 °C for 3 h. 
Untreated and treated cells were then stained with PE-Annexin V and 7-AAD (7-Amino-actinomycin 
D), using the Apoptosis Detection Kit I (BD Pharmingen, NJ, USA) according to the manufacturer’s 
instructions. The cells were acquired by flow cytometry (LSRFortessa, Becton Dickinson) and 
analyzed by FACSDiva software. 
In vitro HTLV-1-infected PBMC proliferation assay. To evaluate the effects of C7a on spontaneous  
in vitro proliferation of HTLV-1-infected PBMC, PBMC from one asymptomatic HTLV-infected 
individual and six patients diagnosed with HAM/TSP were cultured separately in 96-well U-bottom 
culture plates (Costar, Cambridge, MA, 1 × 10
5
 cells/well), in triplicate, at 37 °C in a 5% CO2 
humidified atmosphere. Serial dilutions (0.9 to 60 μM) of C7a and 5 μM CarboxyFluorescein diacetate 
Succinimidyl Ester (CFSE, Invitrogen, Eugene, USA) were added to the cells, and after 24 h 
incubation, cells were harvested, washed two times in 2 mL of PBS containing 1% bovine serum 
albumin, and fixed in PBS containing 4% paraformaldehyde. Analyses were performed using a 
FACSAria (Becton Dickinson) and FlowJo software. At least 10
5
 events were analyzed per sample. 
Proliferation intensity was determined by the percentage of divided cells and the division index. The 
cut-off values were >0.06 for the division index and >5.8% for the percentage of divided cells (3X the 
division index mean and 3X the percentage of divided cells in PBMC controls.).  
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5. Conclusions 
C7a suppresses proliferation of HTLV-1-infected patient PBMCs, induces apoptosis in transformed 
cell lines and significantly enhances the survival of ATLL tumor bearing mice. C7a is a potential novel 
therapeutic treatment for malignant T-cell diseases. 
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